Featured
-
-
Brief Communication
| Open AccessGermline HOXB13 G84E mutation carriers and risk to twenty common types of cancer: results from the UK Biobank
- Jun Wei
- , Zhuqing Shi
- & Jianfeng Xu
-
Article
| Open Access
Addition of an online, validated family history questionnaire to the Dutch FIT-based screening programme did not improve its diagnostic yield
- Victorine H. Roos
- , Frank G. J. Kallenberg
- & Evelien Dekker
-
Article
| Open AccessMultivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer
- Andrés J. Muñoz Martín
- , Israel Ortega
- & Jose M. Soria
-
Genetics and Genomics
| Open Access
Clinically significant mutations in HIV-infected patients with lung adenocarcinoma
- Jonathan Thaler
- , Carlie Sigel
- & Keith Sigel
-
Genetics and Genomics
| Open AccessA comparative study of germline BRCA1 and BRCA2 mutation screening methods in use in 20 European clinical diagnostic laboratories
- Gillian Ellison
- , Andrew Wallace
- & Simon Patton
-
Molecular Diagnostics
| Open Access
Comparative mutational landscape analysis of patient-derived tumour xenografts
- Mariana Brait
- , Evgeny Izumchenko
- & David Sidransky
-
Clinical Study
| Open Access
Screening women for cervical cancer carcinoma with a HPV mRNA test: first results from the Venice pilot program
- Tiziano Maggino
- , Rocco Sciarrone
- & Manuel Zorzi
-
-
-
Genetics and Genomics
| Open Access
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial
- F Fitzal
- , M Filipits
- & M Gnant
-
Genetics and Genomics
| Open Access
Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours
- R R Singh
- , K P Patel
- & R Luthra
-
Molecular Diagnostics
| Open Access
HER2/neu testing in primary colorectal carcinoma
- B Ingold Heppner
- , H-M Behrens
- & C Röcken
-
Genetics and Genomics
| Open Access
Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing
- S Patton
- , N Normanno
- & E Thunnissen
-
Letter to the Editor
| Open Access
Distribution of breast cancer risk from SNPs and classical risk factors in women of routine screening age in the UK
- A R Brentnall
- , D G Evans
- & J Cuzick
-
Molecular Diagnostics
| Open Access
Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
- V Secq
- , J Villeret
- & C Charpin
-
Genetics and Genomics
| Open Access
Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial
- M R Wevers
- , N K Aaronson
- & M G E M Ausems
-
Genetics and Genomics
| Open Access
An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma
- A Linton
- , Y Y Cheng
- & G Reid
-
Epidemiology
| Open AccessA comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing
- K A Metcalfe
- , A Poll
- & S A Narod
-
Genetics and Genomics
| Open Access
A personalised approach to prostate cancer screening based on genotyping of risk founder alleles
- C Cybulski
- , D Wokołorczyk
- & S A Narod
-
Clinical Study
| Open Access
A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the UK
- S Holt
- , G Bertelli
- & C J Phillips
-
Molecular Diagnostics
| Open Access
Assessment of DNA methylation status in early stages of breast cancer development
- A Q van Hoesel
- , Y Sato
- & D S B Hoon
-
Molecular Diagnostics
| Open Access
Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours
- A Pagin
- , F Zerimech
- & M-P Buisine
-
Genetics and Genomics
| Open Access
Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice
- L Heinzerling
- , S Kühnapfel
- & R Schneider-Stock
-
Genetics and Genomics
| Open Access
Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers
- E H Lips
- , L Mulder
- & P M Nederlof
-
Molecular Diagnostics
| Open Access
Accurate and rapid novel genetic diagnosis for detection of sentinel lymph node metastasis in breast cancer patients
- H Iinuma
- , J Tamura
- & T Ikeda
-
Genetics and Genomics
| Open AccessBRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years
- L Robertson
- , H Hanson
- & N Rahman
-
Short Communication
| Open Access
Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
- S Sahebjam
- , R Aloyz
- & L C Panasci
-
Genetics and Genomics
| Open Access
BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
- Z Kote-Jarai
- , D Leongamornlert
- & R Eeles
-
Molecular Diagnostics
| Open Access
KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
- N Knijn
- , L J M Mekenkamp
- & I D Nagtegaal
-
Clinical Study
| Open Access
Morphological predictors of BRCA1 germline mutations in young women with breast cancer
- M C Southey
- , S J Ramus
- & J L Hopper
-
Genetics and Genomics
| Open Access
Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis
- S M Edwards
- , D G R Evans
- & R A Eeles
-
Clinical Study
| Open Access
Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status
- D G R Evans
- , A Moran
- & F Lalloo
-
Clinical Study
| Open Access
A comprehensive evaluation of the accuracy of cervical pre-cancer detection methods in a high-risk area in East Congo
- S Hovland
- , M Arbyn
- & F Karlsen
-
Letter to the Editor
| Open AccessKRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
- E Lopez-Crapez
- , L Mineur
- & P-J Lamy
-
Clinical Study
| Open AccessPerformance of clinical guidelines compared with molecular tumour screening methods in identifying possible Lynch syndrome among colorectal cancer patients: a Norwegian population-based study
- G Tranø
- , W Sjursen
- & L J Vatten
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2